Want to see IN:EMCURE full AI Analyst Report?

Emcure Pharmaceuticals Limited (EMCURE) Price & Analysis

Q: What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹1260.10 and its highest was ₹1944.00 in the past 12 months.

Q: What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹352.94B.

Q: When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.

Q: How were Emcure Pharmaceuticals Limited’s earnings last quarter?

Emcure Pharmaceuticals Limited released its earnings results on May 05, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹13.6 by ₹0.5.

Q: Is Emcure Pharmaceuticals Limited overvalued?

According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.16%. See more information on Emcure Pharmaceuticals Limited dividends here

Q: What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate is 12.6.

Q: How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,680,150 shares outstanding.

Q: What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?

Emcure Pharmaceuticals Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹13.6. Following the earnings report the stock price went down -5.249%.

Q: Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

2 Followers

EMCURE Stock Chart & Stats

₹1345.35

₹31.90(2.25%)

At close: Jan 08 4:00 PM EST

₹1345.35

₹31.90(2.25%)

Day’s Range― - ―

52-Week Range₹1,260.10 - ₹1,944.00

Previous CloseN/A

Volume1.63K

Average Volume (3M)197.42K

Market Cap

₹352.94B

Enterprise Value₹255.38K

Total Cash (Recent Filing)₹6.02B

Total Debt (Recent Filing)₹16.59B

Price to Earnings (P/E)38.2

Beta0.79

Next Earnings

Aug 06, 2026

EPS Estimate

12.6

Next Dividend Ex-DateN/A

Dividend Yield0.16%

Share Statistics

EPS (TTM)22.89

Shares Outstanding189,680,150

10 Day Avg. Volume24,274

30 Day Avg. Volume197,417

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)6.11

Price to Sales (P/S)3.29

P/FCF Ratio61.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,100.00

Price Target Upside56.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)63.7

Revenue Forecast (FY)₹104.41B

Bulls Say, Bears Say

Bulls Say

Revenue & Profitability ImprovementEmcure reported strong FY2026 revenue growth alongside mid‑teens operating margins and roughly ~10% net margin. These sustained improvements indicate better pricing, cost control and scale, enhancing capacity to reinvest in growth, support R&D, and strengthen earnings quality over coming quarters.

Conservative Leverage & Improving ROEThe balance sheet shows low debt relative to equity and year‑over‑year equity growth, with returns on equity improving to the high‑teens. Conservative leverage and rising capital efficiency give the company financial flexibility to fund capex, absorb shocks, or pursue strategic investments without excessive financing risk.

Diversified Revenue StreamsEmcure’s business spans domestic branded generics, international finished‑dose exports and contract manufacturing. This multi‑channel model reduces dependence on one market, smooths manufacturing utilization, and provides channels to offset regional or pricing headwinds, supporting resilient revenue over time.

Bears Say

Weak Cash ConversionFree cash flow covered only ~58% of reported net income and FCF declined modestly year‑over‑year. A persistent earnings‑to‑cash gap suggests working‑capital or conversion issues that constrain internal funding for capex, debt reduction, dividends or strategic investments in the medium term.

Gross Margin VolatilityReported gross margin experienced a sharp swing between FY2025 and FY2026, reducing comparability. Such volatility can reflect input‑cost swings, mix shifts or one‑offs, and undermines predictability of operating profits, complicating budgeting and the sustainability of reported operating margins.

Structural Competition In GenericsEmcure operates largely in branded generics and generic pharmaceuticals where competitive intensity and reimbursement dynamics are structural. Persistent price pressure and market share erosion by low‑cost competitors can compress margins and force continued commercial investment to defend brands over the long run.

Emcure Pharmaceuticals Limited News

Emcure Pharma Files SEBI Dematerialisation Compliance Certificate

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has shared an announcement. Emcure Pharmaceuticals Limited has submitted a confirmation certificate...

15d ago

Emcure Pharmaceuticals Reports Brief Fire-Linked Shutdown at Pune Plant

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has reported a fire...

5M ago

Emcure Pharmaceuticals Confirms SEBI Dematerialisation Compliance for December Quarter

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) just unveiled an update. Emcure Pharmaceuticals has informed the stock exchanges that...

7M ago

Emcure Pharmaceuticals Closes Trading Window Ahead of Q3 FY2026 Results

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has announced the closure...

7M ago

Lilly vs. Novo Nordisk: Who Will Lead India’s Growing Obesity-Drug Market?

U.S.-based Eli Lilly & Co. ($LLY) and Danish drug maker Novo Nordisk ($NVO) are vying to capture a...

7M ago

LLY

NVO

Emcure Pharmaceuticals Allots 7,700 Shares Under Employee Stock Option Scheme

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has issued an announcement. Emcure Pharmaceuticals Limited has announced the allotment of...

7M ago

Emcure Pharmaceuticals Schedules Investor Conference Meeting

An update from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) is now available. Emcure Pharmaceuticals Limited has announced its...

8M ago

Emcure Pharmaceuticals Schedules Virtual AGM with E-Voting

The latest announcement is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals Limited announced the scheduling...

12M ago

EMCURE FAQ

What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹1260.10 and its highest was ₹1944.00 in the past 12 months.

What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹352.94B.

When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.

How were Emcure Pharmaceuticals Limited’s earnings last quarter?

Emcure Pharmaceuticals Limited released its earnings results on May 05, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹13.6 by ₹0.5.

Is Emcure Pharmaceuticals Limited overvalued?

According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.16%. See more information on Emcure Pharmaceuticals Limited dividends here

What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate is 12.6.

How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,680,150 shares outstanding.

What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?

Emcure Pharmaceuticals Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹13.6. Following the earnings report the stock price went down -5.249%.

Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.

Emcure Pharmaceuticals Limited (EMCURE) Earnings & Revenues

Historic Earnings Reports

EMCURE Stock 12 Month Forecast

Average Price Target

₹2,100.00

▲(56.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1278":"₹1,278","2101":"₹2,101","1483.75":"₹1,483.8","1689.5":"₹1,689.5","1895.25":"₹1,895.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1278,1483.75,1689.5,1895.25,2101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1829.75,1850.5384615384614,1871.326923076923,1892.1153846153845,1912.9038461538462,1933.6923076923076,1954.4807692307693,1975.2692307692307,1996.0576923076924,2016.8461538461538,2037.6346153846155,2058.423076923077,2079.2115384615386,{"y":2100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1829.75,1850.5384615384614,1871.326923076923,1892.1153846153845,1912.9038461538462,1933.6923076923076,1954.4807692307693,1975.2692307692307,1996.0576923076924,2016.8461538461538,2037.6346153846155,2058.423076923077,2079.2115384615386,{"y":2100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1829.75,1850.5384615384614,1871.326923076923,1892.1153846153845,1912.9038461538462,1933.6923076923076,1954.4807692307693,1975.2692307692307,1996.0576923076924,2016.8461538461538,2037.6346153846155,2058.423076923077,2079.2115384615386,{"y":2100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1279.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1361.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1378.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1305.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1318,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1431.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1403.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1471,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1445.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1588.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1679.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1829.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >